-ACADIA plans to initiate a Phase 3 study of trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental congenital CNS disorder, in the second half of 2019
-Neuren retains all rights to trofinetide outside of North America
-Neuren to receive US $10 million upfront plus potential milestones of up to US $455 million and royalties
-ACADIA plans to initiate a Phase 3 study of trofinetide for the...
-
- There are more pages in this discussion • 494 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.92 |
Change
0.130(0.94%) |
Mkt cap ! $1.779B | |||
| Open | High | Low | Value | Volume |
| $13.66 | $14.03 | $13.46 | $11.10M | 803.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1608 | $13.91 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.99 | 250 | 1 |
View Market Depth
| Last trade - 16.10pm 05/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |